Claim a Free Sample
Get a preview with key statistics, projections, and trends for this report. Ideal for quick insights.
Send Me a SampleNeed full access?
Purchase ReportMultiplex Assay Market Size & Trends
The size of the global multiplex assay market was valued at USD 1,817.10 million in 2024 and anticipated to grow with a CAGR of 17.5% during the forecast period from 2025 to 2030. A multiplex assay is a method where multiple analytes (e.g., growth factors, chemokines, biomolecules, cytokines, and proteins, etc.) are profiled through detecting and quantifying them in parallel.
Multiplex Assay Market
Size, byProduct, 2024 - 2030{USD Million}
CAGR: 17.50%
Multiplex assay market size is CAGR of 17.5% during the forecast period from 2025 to 2030 request a free sample copy
Multiplex Assay Market
Size, byProduct, 2024 - 2030{USD Million}
Multiplex assay market size is CAGR of 17.5% during the forecast period from 2025 to 2030 request a free sample copy
Key Highlights
- North America accounted for the highest revenue share of 36.34% in 2024.
- The multiplex assay market in the U.S. is experiencing strong growth.
- In terms of type segment, the protein multiplex assay segment accounted for the highest revenue share of 52.99% in 2024.
- In terms of product segment, the consumables segment held 74.42% of the market share in 2024.
- In terms of technology segment, the flow cytometry segment dominated the technology segment with a 34.97% share in 2024.
Multiplex assays have widespread applications in mutation analysis, linkage analysis, identification of pathogens, forensic investigations, gene detection analysis, and more. The major market drivers are increasing incidence of chronic and infectious diseases, substantial benefits of multiplex assays over singleplex and conventional assays, rising utility of multiplex assays in companion diagnostics, and enhanced awareness of early diagnosis. The transition to personalized medicine is a key growth driver for the multiplex assays market. Personalized medicine consists of adapting medical treatment to unique patient characteristics, and for this purpose, accurate and complete diagnostic tools are needed. Multiplex assays permit the simultaneous measurement of several biomarkers, which are required in order to develop targeted therapies. Based on a report by the Personalized Medicine Coalition, 42% of the new medicines approved by the FDA in 2021 were personalized treatments, which indicates growing dependence on sophisticated diagnostic technologies like multiplex assays to enable these therapies.
Increased knowledge regarding early detection of several chronic conditions like cancer can enhance the life quality of patients with a more than threefold increased survival rate upon diagnosis at early stages. Further, early diagnosis can raise the number of treatment choices and minimize the expenses needed for long-term diseases. For example, based on an article released in Avalere in July 2021, patients suffering from non-small cell lung cancer, stomach, and pancreatic cancers, 36% to 53% of the patients have stage four cancer, when the cancer spreads throughout the body and reduces the chances of survival. If identified at the initial phases, the survival rate of 5 years for non-small-cell lung cancer, stomach, and pancreatic cancer can be doubled. The differences raise awareness for the early diagnosis of diseases and can significantly fuel market growth throughout the forecast period.
Apart from this, growing validation of the biomarkers in molecular & protein diagnostics and expanding demand for high-throughput assays and automated systems are anticipated to generate profitable opportunities in the forecast years. Simultaneous biomarker analysis has numerous applications in neurodegenerative diseases, autoimmune diseases, and cancer. Various biomarkers are being identified and validated, and there are good chances of new diagnostics development. Multiplex assay can be applied for protein quantitation in biomarker discovery. The assays enable measurement of many potential protein biomarkers in a statistically significant number of samples and controls. Hence, multiplex assay in biomarker validation enhances the efficiency and speed of providing precise results and can drive the growth of the market in the near future.
Report Coverage & Deliverables
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Market Concentration & Characteristics
The multiplex assay market is characterized by very high innovation, with continuous advances in sensitivity of assays, automation, and convergence with next-generation sequencing (NGS) technologies. Developments such as digital multiplexing and lab-on-a-chip technologies increase throughput and decrease sample size requirements. These developments broadendiagnostics, drug discovery, and biomarker research applications, making multiplex assays essential tools in contemporary molecular and clinical diagnostics.
M&A activity across the multiplex assay market has been strong, fueled by the requirement for businesses to build technological capabilities and global market presence. Strategic biotech firm and assay technology company acquisitions are assisting larger diagnostics firms in enhancing assay portfolios and entering new markets. These mergers speed up innovation cycles, which allow for the quicker deployment of sophisticated testing solutions into clinical and research settings.
Regulatory environments heavily impact the multiplex assay market, particularly for in vitro diagnostics (IVDs). Authority approvals such as the FDA, EMA, and CDSCO are necessary for market access, guaranteeing assay safety, effectiveness, and consistency. Though strict, these regulatory measures ensure product excellence and clinical use. Regulatory changes to accelerate rapid diagnostics, particularly post-COVID-19, ensure quicker time-to-market for multiplex platforms.
Producers are quickly developing their multiplex assay product lines to treat a broader range of diseases, such as infectious diseases, oncology, and autoimmune diseases. New panels are now providing the detection of dozens of targets in parallel, enhancing the diagnostic accuracy and efficiency. Researchers are also releasing customizable research use assays, leading to broad application in academic, pharmaceutical, and clinical environments. This expansion is one of the main market drivers.
The multiplex assay market is experiencing immense geographical growth, especially in Asia Pacific and Latin America, driven by growing healthcare infrastructure, government appropriations, and disease awareness. Local manufacturing and distribution alliances are being set up by companies to address regional needs and streamline regulatory routes. This strategic growth is assisting major players in reaching high-growth emerging markets while making advanced diagnostic technology more accessible.
Type Insights
Protein multiplex assay is the largest segment in terms of revenue share, with a growth of 52.99% in 2024, driven by the growing emphasis on proteomics studies for clinical diagnostics and biomarker research. The search for appropriate biomarkers has picked up a lot in clinical practice, and quantitative analysis of protein is one of the key steps in biomarker discovery. Handling the vast amount of putative protein biomarkers in a large series of controls and samples represents a significant technical challenge. Protein multiplex assays have several benefits in terms of the quantity of data that can be produced, sample requirement, reagent expense, time, and quantity of data that can be produced. For example, as reported in an article released in eClinical Medicine during July 2022, a multiplex protein panel assay was used to ascertain disease severity and prognosis in COVID-19 patients. Therefore, growing uses of protein multiplex assay in proteomics research are expected to drive the market.
The nucleic acid assay is expected to be the fastest-growing segment with CAGR in the next few years. Nucleic acid assay facilitates molecular testing to diagnose human illness, including human disease markers (autoimmune disease and cancer), disease predisposition genetic markers, and diagnostic tests to identify pathogenic disease-causing agents. For example, as per an article released by the American Chemical Society in September 2021, a Lanthanide nanoparticle-based Nucleic acid assay has been employed in diagnosing SARS-CoV-2 in order to attain rapid screening with high precision. Thus, the growing occurrence of infectious and chronic diseases is anticipated to increase the application of nucleic acid multiplex assay in disease diagnosis and expand the market growth throughout the forecast period.
Product Insights
The consumables segment dominated the market share of 74.42% in 2024 and is also anticipated to be the fastest-growing segment over the forecast period. This is because of the periodic buying of consumables and the growth in diagnostic tests. Moreover, various major market players have a wide variety of consumables with benefits like cost savings, analyte customization, and quicker delivery time with strong and stable data. For example, Bio-Techne Corporation, a life science reagent company, provides the most customizable Luminex analyte menu to select from more than 450 analytes and flexible formats. These benefits are likely to enhance the specificity, precision, and stability to provide consistent and accurate results and expand the use of consumables in the market.
The software segment is also expected to account for significant CAGR over the forecast period. Some factors, including higher software efficiency and rising product releases, are anticipated to drive the growth of the segment over the forecast period. As an example, in August 2022, Bio-Techne Corporation released Quantist Luminex data analysis software, which may assist researchers in gaining effective insights from complex data.
Technology Insights
The flow cytometry segment led the technology segment with 34.97% market share in 2024. Flow cytometry has evolved to become a routine tool for basic research and clinical diagnostics. It generates rich multiparametric analysis for thousands of single cells per second. Further, technological growth by different companies and introduction of new flow cytometers also fuels market growth. For example, in June 2021, Thermo Fisher Scientific Inc. introduced an advanced flow cytometer with imaging capability that allows users to gather data and gain a better understanding of the quality and morphology of the cells in such assays.
The multiplex real-time PCR is projected to expand at the highest rate among the forecast years. Multiplex real-time PCR is an adapted form of regular PCR, which amplifies multiple target sequences with different sets of primers in a single PCR reaction. It regulates internal amplification to increase the precision of the negative PCR results. Further, it allows the identification of multiple pathogens in one reaction even from taxonomically distinct groups. These benefits are expected to grow their use in clinical diagnostics and can drive market growth over the forecast period.
End User Insights
The segment of pharmaceutical and biotechnology companies held 41.11% of the market share in 2024. This is attributed to increasing pharma and biotech collaborations and alliances to enhance multiplexing capacity. For example, Becton, Dickinson, and Company and Labcorp partnered in August 2022 to create flow cytometry-based companion diagnostics for treating patients with effective treatment modalities. Flow Cytometry technology facilitates multiplexing and provides high sensitivity in the CDx environment. Therefore, collaborations increase the growth potential of multiplex assays and drive the market.
The hospital and diagnostic laboratory segment is expected to report the highest growth during the forecast period, due to the rising need for quick and precise diagnosis of many chronic ailments. Multiplex assay provides rapid results for several biomolecule targets during a single run and therefore is a better option for the identification of patient diseases. For example, based on the CDC, 9.3 to 45 million are infected with influenza every year, 140,000 - 810,000 hospitalizations, and 12,000 - 61,000 fatalities. The multiplex assay identifies the influenza virus and other pathogens simultaneously to help give a more complete clinical diagnosis for patients who have multiple symptoms related to respiratory viral infections.
Application Insights
The application segment of research and development held 52.01% share in 2024. Usage of multiplex assays is gradually on the rise in drug discovery. The assays are applied in preclinical and clinical phases to analyze toxicity, success of immunotherapy, and biomarkers of drug response. Further, biomarker discovery and validation are crucial in today's era for clinicians to enhance disease diagnosis, detection of cancer at early stages, and track therapeutic responses. Validation of a candidate marker is necessitated in every phase of the biomarker pipeline to achieve clinical usefulness. These usages of multiplex assay in R&D will drive market growth. The clinical diagnostics segment is foreseen to grow the fastest due to the rising incidence of chronic ailments like infectious diseases, cancer, autoimmune diseases, and cardiovascular diseases.
For example, as per the CDC, 3.4 million patients need to be diagnosed for infectious and parasitic diseases in the emergency department. Likewise, as per the CDC in 2022, every 34 seconds a person dies from cardiovascular disease in the US. Multiplex assay is useful to detect different biomarkers for cardiovascular disease in one sample and offer precise, reproducible, and simultaneous measurement of 39 CVD biomarkers in tissue culture samples, serum, and plasma.
Region Insights
North America contributed the largest revenue share of 36.34% in 2024 based on the expanding research & development activities, such as the discovery of new drugs, diagnoses, and treatments. The rising number of chronic conditions like stroke & cancer, and the expanding government expenditure for detecting new biomarkers are expected to propel the segment growth. Besides, leading key regional players are expected to boost the segment growth.
U.S. Multiplex Assay Market Trends
The U.S. multiplex assay market is seeing rapid growth owing to sophisticated healthcare infrastructure, intense R&D spending, and early uptake of innovative diagnostics. The rising incidence of chronic and infectious diseases and the country's focus on precision medicine are fuelling demand for multiplex testing. Additionally, these supportive regulatory avenues by the FDA and the presence of key industry players aid in quick innovation and commercialization. Technological progress in proteomics and genomics, combined with an increasing demand for effective diagnostic solutions, make the U.S. the world leader in the market.
Europe Multiplex Assay Market Trends
The European multiplex assay market is growing consistently, driven by robust academic research, positive healthcare policies, and increased burden of chronic disease. EU programs encouraging early disease detection and personalized medicine are driving the uptake of multiplex platforms. France, Italy, and the Netherlands are seeing more investment in diagnostic labs. Besides, cooperation between pharmaceutical and biotechnology companies in drug development is driving the competitiveness of multiplex assay use in clinical trials. Robust but lenient cooperation regulatory environments guarantee high standards of quality and sustained regional innovation.
The UK multiplex assay market is increasing owing to robust government support for genomics research and initiatives at NHS to embrace early disease detection. Initiatives such as Genomics England and public-private collaborations are driving the application of multiplex assays in personalized medicine. A growing emphasis on cancer diagnosis and infectious disease testing is contributing to expanding market demand. Additionally, the UK's thriving biotech cluster and efficient regulatory environment provide a favorable site for diagnostics innovation and commercialization.
Germany's multiplex assay market is fueled by its strong medical tech industry, comprehensive healthcare network, and strong clinical research environment. The nation's focus on precise diagnostics and lab automation has prompted hospitals and research institutions to implement multiplex testing. Cancer and infectious disease research funding from the government, together with the presence of top biotech firms and pharmaceutical companies, also drives market expansion. Germany is also favored with a highly qualified labor force and regulatory efficiency that favors the development and dissemination of advanced diagnostic assays.
Asia Pacific Multiplex Assay Market Trends
Asia Pacific is anticipated to experience the most rapid growth in the multiplex assay market over the forecast period. This can be attributed to the increasing number of hospitals across developing nations, growing R&D function, increasing demand for healthcare infrastructure, as well as investments by emerging players from the region. For example, in 2021, QuantuMDx acquired a USD 10.9 million investment from Vita Spring and signed a corporate partnership with Sansure Biotech to advance the multiplexing capacity in China. Further, an increase in cancer is caused by tobacco use. For example, half of the world's tobacco is cultivated and consumed by Asia Pacific citizens. Therefore, the steady increase in the number of individuals getting screened in the region is expected to spur market growth in the near future.
China multiplex assay market is growing at a rapid pace, aided by robust government spending on healthcare modernization and biotechnology. The increasing incidence of infectious and chronic diseases drives demand for quick, accurate diagnoses. With national initiatives such as "Made in China 2025" encouraging biotech innovation, domestic firms are increasingly establishing multiplex technologies. Joint ventures between Chinese hospitals and multinational companies are speeding up clinical application. China's huge population base and continuing reforms to regulatory approval procedures are also facilitating market penetration.
The Japanese market for multiplex assays is expanding steadily as a result of an aging population, high health standards, and emphasis on early detection of disease. The nation invests considerably in genomic science and personalized medicine, and multiplex assays become essential diagnostic tools. Government-sponsored programs and partnerships with universities propel R&D in molecular diagnostics. A robust indigenous pharmaceutical sector, combined with regulatory agencies supporting innovation while upholding high quality standards, also makes the Japanese market favorable.
Latin America Multiplex Assay Market Trends
The Latin America multiplex assay market is seeing growth gradually, driven by increasing investments in healthcare and heightened awareness of sophisticated diagnostics. Brazil, Mexico, and Argentina are key markets, as developing laboratory infrastructure and rising demand for infectious disease testing drive growth. While regulatory obstacles and the lack of reimbursement frameworks present challenges, collaborations with multinational diagnostics firms and public health activities are aiding growth in access. Market potential is high with governments increasingly focusing on disease prevention and early diagnosis approaches.
Middle East and Africa Multiplex Assay Market Trends
The Middle East and Africa multiplex assay market exhibits growing expansion due to increasing healthcare expenditure and the spread of infectious diseases. The UAE and Saudi Arabia are investing in diagnostic technology as part of overarching healthcare modernization. In Africa, international aid initiatives and partnerships with NGOs are making multiplex testing adoptable, particularly for conditions such as HIV and tuberculosis. With limited infrastructure and considerable costs, growth could be limited without sustained investment.
Major Multiplex Assay Company Developments
Major companies in the space are adopting many strategies including partnerships, new technology & product launch, and partnerships to improve their market position. For example, in October 2024, 10x Genomics, Inc. released two new Chromium products that increase access to single-cell analysis. The new GEM-X Flex and GEM-X Universal Multiplex provide significant improvements in performance, workflow speed, and affordability. These innovations seek to make single-cell analysis more accessible and convenient for more researchers and applications in many different areas of science.
Key Multiplex Assays Companies
The following are the leading companies in the multiplex assays market. These companies collectively hold the largest market share and dictate industry trends.
- Luminex Corporation
- Bio-Rad Laboratories, Inc.
- Abcam plc.
- Seegene Inc.
- Merck KGaA
- Assay Genie.
- Promega Connections
- QIAGEN N.V.
- Thermo Fisher Scientific
- PerkinElmer Inc.
- Advanced Cell Diagnostics, Inc.
- R&D Systems, Inc.
Recent Development
-
In March 2025, Sphere Bio, a company at the forefront of picodroplet-based microfluidics for functional single-cell analysis and isolation, launched its Cyto-Cellect Human IgG Kappa and Viability Assay Kit. This is the first multiplexed assay designed specifically for the company's recently released Cyto-Mine Chroma platform, which is a major breakthrough in high-throughput single-cell screening capabilities.
QIAGEN made a significant improvement to its QIAcuity Digital PCR (dPCR) system in January 2025 by doubling the number of targets that may be analyzed at the same time from a single biological sample. The upgrade greatly increases the analytical capability of the system by allowing for broader and more efficient multiplexing testing.
Augurex Life Sciences Corp. launched its Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs) in November 2024, enabling the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA). New Day Diagnostics created the test, which utilizes these ASRs and can only be accessed through physician orders. Intended to facilitate earlier detection of axSpA, the test is designed to shorten diagnostic delays and improve outcomes for patients by allowing clinical intervention to occur sooner.
In April 2024, Bio-Rad Laboratories, Inc. launched its initial ultrasensitive multiplexed digital PCR assay—the ddPLEX ESR1 Mutation Detection Kit. The new assay increases Bio-Rad's Droplet Digital PCR (ddPCR) offering in the oncology market, enabling applications within translational research, therapy selection, and disease monitoring via ultrahigh sensitivity and multiplexed mutation detection.
Multiplex Assay Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 1,974.64 million |
|
Revenue forecast in 2030 |
USD 4,412.72 million |
|
Growth rate |
CAGR of 17.5% from 2025 to 2030 |
|
Base year for estimation |
2024 |
|
Historical data |
2018 - 2023 |
|
Forecast period |
2025 - 2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Product, type, technology, application, end user, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Sweden; Denmark; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
Bio-Rad Laboratories, Inc.; Abcam plc.; R&D Systems, Inc.; Merck KGaA; Assay Genie; Promega Connections; QIAGEN N.V.; Thermo Fisher Scientific; Luminex Corporation; Perkin Elmer Inc.; Advanced Cell Diagnostics, Inc.; Seegene Inc. |
|
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Global Multiplex Assays Market Report Segmentation
Product Outlook (Revenue, USD Million, 2018 - 2030)
-
-
Consumables
-
Instruments
-
Software
-
-
Type Outlook (Revenue, USD Million, 2018 - 2030)
-
Protein Multiplex Assays
-
Planar Protein Assays
-
Bead-Based Protein Assays
-
-
Nucleic Acid Multiplex Assays
-
Planar Protein Assays
-
Bead-Based Protein Assays
-
-
Cell-Based Multiplex Assays
-
-
Technology Outlook (Revenue, USD Million, 2018 - 2030)
-
Flow Cytometry
-
Fluorescence Detection
-
Luminescence
-
Multiplex Real-Time PCR
-
Other Technologies
-
-
Application Outlook (Revenue, USD Million, 2018 - 2030)
-
Research & Development
-
Drug Discovery & Development
-
Biomarker Discovery & Validation
-
-
Clinical Diagnostics
-
Infectious Diseases
-
Cancer
-
Cardiovascular Diseases
-
Autoimmune Diseases
-
Nervous System Disorders
-
Metabolism & Endocrinology Disorders
-
Other Diseases
-
-
-
End User Outlook (Revenue, USD Million, 2018 - 2030)
-
Pharmaceutical & Biotechnology Companies
-
Hospitals & Diagnostic Laboratories
-
Research & Academic Institutes
-
Other End Users
-
-
Regional Outlook (Revenue, USD Million, 2018 - 2030)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Frequently Asked Questions
The global multiplex assay market size was estimated at USD 2.05 billion in 2022 and is expected to reach USD 1.47 billion in 2023.
The global multiplex assay market is expected to witness a compound annual growth rate of 14.77% from 2023 to 2030 to reach USD 3.87 billion in 2030.
The consumables segment held the dominant share of the market. This is due to the recurring purchase of consumables along with the rise in number of diagnostic tests.
The key market players key competing in the multiplex assay market include Bio-Rad Laboratories, Inc. Thermo Fisher Scientific, Seegene Inc., Luminex Corporation, Abcam plc., Promega Connections, QIAGEN N.V., Perkin Elmer Inc.
The key factors driving the multiplex assay market include the growing prevalence of chronic and infectious diseases, significant advantages of multiplex assays over singleplex and traditional assays, increasing applications of multiplex assays in companion diagnostics and rising awareness of early diagnosis.